LoQus23 Therapeutics Ltd.

https://www.loqus23.com

LoQus23 is a biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington’s Disease and other triplet repeat disorders. Huntington’s disease is an autosomal dominant neurodegenerative disorder for which there is currently no disease modifying treatment available and which currently has 30,000 patients in the US alone. LoQus23’s approach has the potential to stop DNA instability and therefore slow neurodegeneration in these diseases. LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches. Oral small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for patients compared with other advanced treatment modalities. LoQus23 has a highly experienced leadership team, built on world-class science. It was originally established in 2019 by Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan CBE, FMedSci, Entrepreneurs in Residence at SV Health Investors’ Dementia Discovery Fund, which also acted as the initial seed investor. *

	Start	2019-03-29 established
	Industry	BIOTECH
	Person	Reynolds, David (AstronauTx 201908 CEO)
	Person 2	Sandham, Andrew (Andy) (Abingworth 200601– Venture Partner + Kymab 201007 CEO)

	Region	Cambridge, Cambridgeshire
	Country	United Kingdom (GB)
	Street	Babraham Research Campus Building 522
	City	CB22 3AT Cambridge
		Address record changed: 2024-10-04

Basic data	Employees	n. a.

		* Document for »About Section«: LoQus23 Therapeutics Ltd.. (10/2/24). "Press Release: LoQus23 Therapeutics Announces £35 Million (c.$43 Million) Series A Financing to Advance Its Small Molecule Somatic Expansion Inhibition Therapy for Huntington’s Disease". Cambridge.

		Record changed: 2024-10-05